Company Name, Ticker, Customers, else..

Alzamend Neuro Inc (NASDAQ: ALZN)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Alzamend Neuro Inc 's

Name: Alzamend Neuro Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ALZN Sales vs. its Competitors Q1 2026

Comparing the current results to its competitors, Alzamend Neuro Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 15.2 %, recorded in the same quarter.

• List of ALZN Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Alzamend Neuro Inc , faster than the decline experienced by the competitors of -0 %. recorded a net loss, despite income increase by most of its competitors of -0 %

<< ALZN Stock Performance Comparisons

Alzamend Neuro Inc 's Comment on Competition and Industry Peers

The company operates in a competitive pharmaceutical and biotechnology industry marked by rapid technological changes. Its competitors include large and small pharmaceutical and biotechnology firms, specialty pharmaceutical companies, generic drug companies, academic institutions, government agencies, and research institutions. Competition is influenced by the potential indications for which products receive regulatory approval. Key competitive factors include the timing of market introductions, speed of product development, clinical trials, regulatory approval, and manufacturing.

<< See the full list of ALZN competitors

*Market share is calculated based on total revenue.

ALZN's Stock Performance relative to its Competitors

Publicly Traded Peers of Alzamend Neuro Inc

Alto Neuroscience Inc
Share Performance

+41.16%

This Quarter

Alto Neuroscience Inc

Profile

The company is a clinical-stage biopharmaceutical firm focused on developing personalized neuropsychiatric treatments utilizing biomarkers.

More about Alto Neuroscience Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 1,295.093 mill.	$ - mill.	$ -84.238 mill.

Cybin Inc
Share Performance

-18.02%

One Year

Cybin Inc

Profile

Helus Pharma develops therapeutics for mental health and neurological conditions.

More about Cybin Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 167.442 mill.	$ 159.148 mill.	$ -86.663 mill.

Definium Therapeutics Inc
Share Performance

+169.94%

This Year

Definium Therapeutics Inc

Profile

Definium Therapeutics develops pharmaceutically optimized psychedelic drug candidates.

More about Definium Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 4,075.411 mill.	$ - mill.	$ -353.785 mill.

Bright Minds Biosciences Inc
Share Performance

-2.19%

This Quarter

Bright Minds Biosciences Inc

Profile

Bright Minds Biosciences Inc is a biotechnology company that focuses on developing novel therapies for neuropsychiatric diseases. Their business model involves conducting research and development to discover and develop proprietary drug candidates, with the aim of partnering or licensing them to pharmaceutical companies for further clinical development and commercialization.

More about Bright Minds Biosciences Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 414.196 mill.	$ - mill.	$ -9.368 mill.

Quantum Biopharma Ltd
Share Performance

-39.26%

30 Days

Quantum Biopharma Ltd

Profile

Fsd Pharma Inc's business model is centered around the development and production of pharmaceutical-grade cannabis products. The company aims to leverage its in-house cultivation facility, research and development capabilities, and strategic partnerships to create innovative cannabis-based therapies for various medical conditions. Fsd Pharma focuses on pursuing licensing and acquisition opportunities to expand its presence in the global cannabis market.

More about Quantum Biopharma Ltd 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ - mill.	$ - mill.	$ -37.457 mill.

16 more competitors available

Sources: Alzamend Neuro Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Monday, September 14, 2026 3:49 AM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Alzamend Neuro Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.